Female Patients With Overactive Bladder Syndrome or Female Patients With Urgency or Urgency Urinary Incontinence
Conditions
Brief summary
Evaluation of use of low dose tadalafil 5 mg daily for treatment of female OAB syndrome
Detailed description
90 female patients with overactive bladder syndrome divided into 3 groups group A subjected to daily low dose tadalafil 5 mg ,group B subjected to tolterodine and group C to placebo. They are evaluated as using OAB symptoms score for 6 months follow up
Interventions
DRUGLow dose tadalafil 5 mg
Efficacy of daily low dose tadalafil 5mg for treatment of female overactive bladder syndrome or urgency with or without urgency urinary incontinence
DRUGTolterodine 4 Mg Oral Capsule, Extended Release
To compare efficacy of low dose tadalafil 5 mg to tolterodine 4 mg extended release in treatment of female overactive bladder
DRUGPlacebo
Placebo drugs
Sponsors
Kasr El Aini Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Healthy volunteers
No
Inclusion criteria
* any female with overactive bladder syndrome, urgency with or without urgency urinary incontinence
Exclusion criteria
* Active Urinary tract infection * neurologic abnormality * Pure Stress urinary incontinence
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy of daily low dose tadalafil 5mg in treatment of female overactive bladder syndrome: 6 months follow up | 6 months | Evaluation of efficacy of tadalafil 5 mg |
Countries
Egypt
Outcome results
None listed